NASDAQ: BIVIBiovie Inc Stock
$0.84+0.05 (+6.33%)
Updated Apr 17, 2025
BIVI Price
$0.84
Fair Value Price
$1.96
Market Cap
$15.52M
52 Week Low
$0.62
52 Week High
$7.50
P/E
-0.24x
P/B
0.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$22M
Beta
1.5
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BIVI Overview
BioVie Inc. is a clinical-stage biotechnology company that discovers, develops, and commercializes drug therapies. Its lead product, BIV201, is a drug approved in 40 countries to treat related complications from liver cirrhosis. BioVie was incorporated in 2013 and is based in Santa Monica, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BIVI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BIVI
Ranked#213 of 463
Ranked#213 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important BIVI news, forecast changes, insider trades & much more!
BIVI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIVI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIVI ($0.84) is undervalued by 57.14% relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BIVI ($0.84) is significantly undervalued by 57.14% relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BIVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIVI due diligence checks available for Premium users.
Valuation
BIVI fair value
Fair Value of BIVI stock based on Discounted Cash Flow (DCF)
Price
$0.84
Fair Value
$1.96
Undervalued by
57.19%
BIVI ($0.84) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIVI ($0.84) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIVI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.24x
Industry
-177.72x
Market
27.98x
BIVI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.65x
Industry
4.05x
BIVI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIVI's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.1M
Profit Margin
0%
BIVI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$25.7M
Liabilities
$1.8M
Debt to equity
0.07
BIVI's short-term assets ($24.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIVI's short-term assets ($24.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIVI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIVI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.6M
Investing
$0.0
Financing
$13.0M
BIVI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIVI vs Biotech Stocks
Biovie Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.